Skip to content
No picture yet

Losartan/HCTZ 50 mg / 12.5 mg – DIN 02427648

Losartan/HCTZ is Losartan Potassium and Hydrochlorothiazide 50 mg / 12.5 mg (tablet), sold in Canada. It is used for high blood pressure and quitting smoking. It is supplied by Sanis Health Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Losartan Potassium and Hydrochlorothiazide 50 mg / 12.5 mg

Brand
Losartan/HCTZ
Strength
Losartan Potassium 50 mg / Hydrochlorothiazide 12.5 mg
Used for
High blood pressure and quitting smoking
Form
Tablet
Manufacturer
Sanis Health Inc
Drug class
ARB (blood pressure medicine)
Sold in
Canada
DIN
02427648

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Losartan and Hydrochlorothiazide pills and guides

What is Losartan and Hydrochlorothiazide used for?

Losartan and Hydrochlorothiazide is used for high blood pressure and quitting smoking.

Medicine type
ARB (blood pressure medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label

Hypertension

Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.

Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents.

Hypertensive Patients with Left Ventricular Hypertrophy

Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients.

From the FDA-approved label on DailyMed (published Aug 10, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02427648.
  • It names Losartan/HCTZ, Losartan Potassium and Hydrochlorothiazide 50 mg / 12.5 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Losartan/HCTZ by Sanis Health Inc.

In Canada: prescription only.

Ingredients

Active: Losartan Potassium, Hydrochlorothiazide

Other Losartan and Hydrochlorothiazide pills